SCHEMBL2959258

SCHEMBL2959258

NS(=O)(=O)N1CCN(c2ccccc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.57
HPGD P15428 1/20 0.57
TSHR P16473 1/20 0.57
POLB P06746 2/20 0.57
THRB P10828 1/20 0.57
LMNA P02545 3/20 0.53
PKM P14618 1/20 0.53
MAPK1 P28482 1/20 0.53
HTT P42858 1/20 0.53
HSD17B10 Q99714 1/20 0.53
CA12 O43570 2/20 0.51
CA1 P00915 2/20 0.51
CA2 P00918 2/20 0.51
CA9 Q16790 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
CA7 P43166 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CYP2C9 P11712 1/20 0.50
MAPT P10636 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5500274 0.98 ALDH1A1 (0.56) ALDH1A1HPGDTSHRPOLBTHRB
SCHEMBL2966745 0.83 GAA (0.74) ALDH1A1THRBMEN1KMT2ACYP2C9
SCHEMBL2103070 0.82 CYP2C9 (0.72) ALDH1A1HPGDTSHRPOLBLMNA
SCHEMBL2103067 0.82 ALDH1A1 (0.56) ALDH1A1HPGDTSHRPOLBTHRB
SCHEMBL4671150 0.80 MEN1 (0.65) ALDH1A1HPGDLMNAHTTCA12
SCHEMBL13591281 0.80 AKR1C3 (0.47) ALDH1A1HPGDTSHRPOLBTHRB
SCHEMBL13591219 0.80 MEN1 (0.69) ALDH1A1TSHRLMNAPKMMAPK1
SCHEMBL1487309 0.80 CHKA (0.55) TSHRPOLBTHRBMAPK1CA12
SCHEMBL616835 0.80 ALDH1A1 (0.78) ALDH1A1HPGDPOLBTHRBLMNA
SCHEMBL19634850 0.80 KMT2A (0.64) ALDH1A1HPGDTSHRMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1812393-B1 METHYL 2-[(3S)-[3-[(2E)-(7-CHLOROQUINOLIN-2-YL) ETHENYL]PHENYL]-3-HALOPROPYL]-BENZOATE ESTER MATRIX LAB LTD (IN) 2011-12-28 EP claimed
CN-1997370-B Use of N-sulfamoyl-N' -arylpiperazines for the production of medicaments for the prophylaxis or treatment of obesity and related diseases SOLVAY PHARM BV 2011-06-01 CN claimed
EP-1812393-A2 \"METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES” Matrix Laboratories Ltd (IN) 2007-08-01 EP claimed
CN-1997370-A Medicaments containing N-sulfamoyl-N' -arylpiperazines for the prophylaxis or treatment of obesity and related diseases SOLVAY PHARM GMBH (DE) 2007-07-11 CN claimed
EP-1750712-A2 MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS Solvay Pharmaceuticals GmbH (DE) 2007-02-14 EP claimed
WO-2006008750-A2 METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES MATRIX LABORATORIES LTD (IN) 2006-01-26 WO claimed
WO-2005110413-A2 MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-11-24 WO claimed
US-20050261292-A1 Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions SOLVAY PHARMACEUTICALS GMBH (DE) 2005-11-24 US claimed
US-10844032-B2 Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors VANDERBILT UNIVERSITY (US) 2020-11-24 US disclosed
US-20180312485-A1 SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2018-11-01 US disclosed
US-10093640-B2 Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors VANDERBILT UNIVERSITY (US) 2018-10-09 US disclosed
US-20150336925-A1 SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY (US) 2015-11-26 US disclosed
WO-2014047427-A2 SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY (US) 2014-03-27 WO disclosed
EP-1812393-B1 METHYL 2-[(3S)-[3-[(2E)-(7-CHLOROQUINOLIN-2-YL) ETHENYL]PHENYL]-3-HALOPROPYL]-BENZOATE ESTER MATRIX LAB LTD (IN) 2011-12-28 EP disclosed
US-20070117823-A1 N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof SOLVAY PHARMACEUTICALSS GMBH (DE) 2007-05-24 US disclosed
WO-2007054580-A1 N-SULFAMOYL-N’-BENZOPYRANPIPERIDINES AS INHBITORS OF CARBONIC ANHYDRASES SOLVAY PHARMACEUTICALS GMBH (DE) 2007-05-18 WO disclosed
EP-1750712-A2 MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS Solvay Pharmaceuticals GmbH (DE) 2007-02-14 EP disclosed
WO-2006008750-A2 METHYL 2-[(3S)-[3-[(2E)-(7-CHLORO QUINOLIN-2-YL) ETHENYL] PHENYL]-3-HALOPROPYL] BENZOATES MATRIX LABORATORIES LTD (IN) 2006-01-26 WO disclosed
WO-2005110413-A2 MEDICAMENTS CONTAINING N-SULFAMOYL-N'-ARYLPIPERAZINES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-11-24 WO disclosed
US-20050261292-A1 Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions SOLVAY PHARMACEUTICALS GMBH (DE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312485-A1 SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCLAF1 ALDH1A1 1179/4885HPGD 3486/4885TSHR 4640/4885
US-20150336925-A1 SUBSTITUTED BENZOFURAN, BENZOTHIOPHENE AND INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCLAF1 ALDH1A1 1179/4885HPGD 3486/4885TSHR 4640/4885
US-20070117823-A1 N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof SCN2A, NAPEPLD, SCN5A ALDH1A1 605/4885HPGD 523/4885TSHR 3092/4885
US-20050261292-A1 Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions GPR119, FABP4, SULT2A1 ALDH1A1 265/4885HPGD 1048/4885TSHR 1441/4885
US-10093640-B2 Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors MCL1, BCL2L1, BCLAF1 ALDH1A1 1179/4885HPGD 3486/4885TSHR 4640/4885
US-10844032-B2 Substituted benzofuran, benzothiophene and indole Mcl-1 inhibitors MCL1, BCL2L1, BCLAF1 ALDH1A1 1179/4885HPGD 3486/4885TSHR 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.